OTC Athlete’s Foot Drug Labeling Changes Supported By NDAC Panel, Industry
This article was originally published in The Tan Sheet
Executive Summary
Current labeling for OTC drugs for Tinea pedis (athlete's foot) may mislead consumers toward greater expectations of benefit and should be changed, FDA's Nonprescription Drugs and Dermatologic and Ophthalmic Drugs advisory committees agreed unanimously at a May 6 meeting in Rockville, Md